Tinnen Quoted in Reorg About Termination Fees in Alexion Pharmaceuticals Proposed Acquisition of Portola Pharmaceuticals

Partner Clyde Tinnen was quoted in the Reorg article, “Past Alexion Guidance Bodes Well for Quick Review,” about Alexion’s planned acquisition of Portola in 2020. Although the deal is expected to withstand regulatory scrutiny, Portola would owe Alexion a termination fee in certain circumstances. “All things being equal, break up fees typically do provide a strong protective device for buyers to keep sellers in a deal,” Tinnen said.

(Suscripción obligatoria)